Joanne M. Donovan

Joanne M. Donovan

Signal active

Chief Medical Officer

Contact Information

Social

Primary Organization

Edgewise Therapeutics

Edgewise Therapeutics

Founded

2017

Employees

51-100

Industry

Biotechnology, Health Care, Biopharma

Bio

Joanne Donovan, M.D., Ph.D., has served as our Chief Medical Officer since July 2011. In addition, since 1989, she worked as a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr. Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate clinical professor of medicine. From 1998 to July 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme Corporation, a publicly traded biotechnology company, which she joined through its acquisition of GelTex. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women’s Hospital.

Location

Boston, Massachusetts, United States, North America

Jobs history

1

Edgewise Therapeutics

Chief Medical Officer

Invalid date - Current

Educations

1

N/A

Profile Resume

Joanne M. Donovan is the Chief Medical Officer at Edgewise Therapeutics, based in United States, North America. With a background in Biotechnology, Joanne M. Donovan has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.

Recommendation from your interest

N/A

Products and Innovations

0

There is no product and inovations for this profile.

Achievements

0

There is no Achievements for this profile.

Publications

0

There is no publication for this profile.

Recent Activity

There is no recent news or activity for this profile.